Singapore, 22 February 2022: Hilleman Laboratories, an organisation with a mission to develop affordable vaccines and biologics against infectious diseases, today broke ground on a 30,000 square foot current Good Manufacturing Practices (cGMP) facility at 138 Depot Road as part of its official launch in Singapore. The ceremony was graced by Mr Gan Kim Yong, Minister for Trade and Industry, Singapore and was also attended by members of the Hilleman Laboratories Board of Directors, namely Chairman Mr Sanat Chattopadhyay, Dr Gerd Zettlmeissl, Professor Gagandeep Kang, and CEO Dr Raman Rao, as well as representatives of Hilleman Laboratories’ partner organisations.
The cGMP facility, together with an existing research and development (R&D) facility at Biopolis, form an SGD 80 million (USD 58 million) vaccine and biologics development and manufacturing hub, the first of its kind in Singapore. The hub will provide end-to-end product development solutions from concept to cGMP and Phase II clinical development, supporting the development of affordable, high-value vaccines and biologics for Singapore as well as low- and middle-income countries using innovative technology platforms. Expected to be fully operational by early 2023, the cGMP facility will supply clinical trial materials up to Phase II stage, and has been designed to pivot to manufacture vaccines for Singapore’s use during pandemics.
